comprises a light chain CDR1 sequence of SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:23 and a light chain CDR3 sequence of SEQ ID NO:25.

5. A humanized monoclonal antibody or antibody fragment having a heavy chain variable domain and a light chain variable region comprising the amino acid sequences of SEQ ID NO:27 and SEQ ID NO:26, respectively; SEQ ID NO:28 and SEQ ID NO:26, respectively; SEQ ID NO:29 and SEQ ID NO:26, respectively; SEQ ID NO:30 and SEQ ID NO:26, respectively; SEQ ID NO:32 and SEQ ID NO:31, respectively; SEQ ID NO:33 and SEQ ID NO:31, respectively; SEQ ID NO:34 and SEQ ID NO:31, respectively; SEQ ID NO:35 and SEQ ID NO:31, respectively; SEQ ID NO:37 and SEQ ID NO:36, respectively; SEQ ID NO:38 and SEQ ID NO:36, respectively; SEQ ID NO:39 and SEQ ID NO:36, respectively; SEQ ID NO:40 and SEQ ID NO: 36, respectively.

~~6. An isolated antibody or antigen-binding fragment that specifically binds to human CD40, comprising~~

~~a) a humanized heavy chain variable domain comprising a framework region having an amino acid sequence at least 90% identical to the amino acid sequence of the framework region of the human variable domain heavy chain amino acid sequence of SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 or SEQ ID NO:35, and comprising a light chain amino acid sequence at least 90% identical to a corresponding light chain variable of SEQ ID NO:31; or~~

~~b) a humanized heavy chain variable domain comprising a framework region having an amino acid sequence at least 90% identical to the amino acid sequence of the framework region of the human variable domain heavy chain amino acid sequence of SEQ ID NO: 37, SEQ ID NO:38; SEQ ID NO:39 or SEQ ID NO: 40, and comprising a light chain amino acid sequence at least 90% identical to a corresponding light chain of SEQ ID NO:36.~~

~~7. A humanized monoclonal antibody or antigen binding fragment of an antibody wherein said antibody or antigen binding fragment of the antibody specifically binds to human CD40 having an antagonistic activity IC50 of less than 1nM and has no~~

~~agonism up to 100 μg/ml in B cell proliferation and wherein said antibody or antigen binding fragment of the antibody is further characterized in that the antibody or antigen binding fragment of the antibody has an in vivo half life in non-human primates that is at least 10 days; and wherein said antibody or antigen binding fragment of the antibody optionally has a half-life in cynomolgus monkeys of greater than 8 days at a dose of less than 30 mg/kg.~~

~~8~~6. An antibody of any of claims 1-~~7~~ 5 for use in blocking the function of human CD40 in a mammal, wherein said antibody is in an amount sufficient to block a CD40 mediated immune response in said mammal.

~~9~~7. An antibody of any of claims 1-~~7~~ 5 for use in treating or ameliorating a disesase or disorder in a mammal, wherein said antibody is in an amount sufficient to decrease one or more of the symptoms of the disease or disorder in the mammal.

~~10~~8. The antibody of claim ~~9~~7, wherein the disease or disorder is selected from the group consisting of: graft v. host disease, autoimmune or inflammatory disease, and CD40-related disorder.

~~11~~9. The antibody of claim ~~10~~8, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Good pasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs

~~12~~10. The antibody of any of claims ~~8~~6-~~11~~9, further comprising a second therapeutic agent ~~selected~~.

~~13~~11. The antibody of any of claims ~~8~~6-~~12~~10, wherein said antibody is formulated for administration by a parenteral route, intravenous route or subcutaneous route of administration.

~~14~~12. Use of an antibody of any claims 1-~~7~~5 in the manufacture of a medicament for the treatment or amelioration of a disease or disorder selected from the group consisting of: graft v. host disease, autoimmune or inflammatory disease, and CD40-related disorder.

~~15~~13. The use of claim ~~14~~12, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Good pasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis.

~~16~~14. A pharmaceutical composition comprising: (i) the antibody of any of claims 1-~~7~~5; and (ii) a pharmaceutically acceptable excipient; and wherein the antibody or antigen binding fragment thereof is optionally conjugated to a second agent.

~~17~~15. An isolated polynucleotide or polynucleotides encoding a heavy chain variable region amino acid sequence ~~or~~ and a light chain variable region, wherein the heavy chain variable region amino acid sequence comprises any of SEQ ID NO: 1 to 4, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO: 29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID